Non-enzymatic protein glycation

Non-enzymatic protein glycation, also known as the Maillard reaction, is a spontaneous chemical process where reducing sugars react with the amino groups of proteins, lipids, or DNA (Source: StatPearls, NBK547680). This reaction progresses from unstable Schiff bases to stable Amadori products, eventually forming irreversible Advanced Glycation End-products (AGEs) that accumulate on long-lived tissue proteins like collagen and crystallin (Source: PubMed, PMID: 11738000). Pathologically, this process is accelerated in chronic hyperglycemia, contributing to the microvascular and macrovascular complications of diabetes, as well as neurodegenerative diseases and aging (Source: NIH, National Institute of Diabetes and Digestive and Kidney Diseases). Therapeutic interventions focus on inhibiting AGE formation using dicarbonyl scavengers like aminoguanidine or breaking established cross-links with agents like alagebrium (Source: PubMed, PMID: 15181025). Despite promising preclinical data, many glycation inhibitors have faced challenges in clinical trials due to safety concerns or insufficient efficacy in reversing established damage.

Other names

Maillard reactionGlycationNon-enzymatic glycosylationProtein glycation

Inhibition of the formation of advanced glycation end-products (AGEs) by scavenging reactive dicarbonyl intermediates (e.g., methylglyoxal), inhibiting the rearrangement of Amadori products, or breaking existing AGE cross-links (Source: PubMed, PMID: 24354186).